Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

September 18, 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
September 4, 2024

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
August 28, 2024

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
August 8, 2024

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 1, 2024

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Show per page